Activation of Reactive Versus Malignant T Cells in Cutaneous T Cell Lymphoma: Role of Abnormal Antigen Presenting Cells and T Cell Activating Molecules

1994 ◽  
pp. 29-38 ◽  
Author(s):  
Kevin D. Cooper ◽  
May-Sen Lee ◽  
Darius Mehregen ◽  
Erik Hansen ◽  
Ole Baadsgaard ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cell Lymphoma ◽  
Antigen Presenting Cells ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Antigen Presenting ◽  
Malignant T Cells

scholarly journals Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients

Oncotarget ◽  
2015 ◽  
Vol 6 (16) ◽  
pp. 14374-14384 ◽  
Author(s):  
Ieva Bagdonaite ◽  
Hans H. Wandall ◽  
Ivan V. Litvinov ◽  
Claudia Nastasi ◽  
Jürgen C. Becker ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Splice Variant ◽  
Cell Lymphoma ◽  
Ectopic Expression ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Malignant T Cells

Cutaneous T-Cell Lymphoma Lesional Epidermal Cells Activate Autologous CD4+ T Lymphocytes: Involvement of Both CD1+OKM5+ and CD1+OKM5− Antigen-Presenting Cells

1990 ◽  
Vol 94 (4) ◽  
pp. 485-491 ◽  
Author(s):  
Erik R. Hansen ◽  
Ole Baadsgaard ◽  
Steen Lisby ◽  
Kevin D. Cooper ◽  
Kristian Thomsen ◽  
...  
Keyword(s):  
T Cell ◽  
T Lymphocytes ◽  
Cell Lymphoma ◽  
Antigen Presenting Cells ◽  
Epidermal Cells ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Antigen Presenting

scholarly journals High IKZF2 Expression in Malignant T cells Promotes Disease Progression in Cutaneous T cell Lymphoma

2021 ◽  
Author(s):  
Bufang Xu ◽  
Fengjie Liu ◽  
Yumei Gao ◽  
Jingru Sun ◽  
Yingyi Li ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Disease Progression ◽  
Immune Escape ◽  
Cell Lymphoma ◽  
Malignant Cell ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Tumor Immune Escape ◽  
Malignant T Cells

Cutaneous T cell lymphoma is a generally indolent disease derived from skin-homing mature T cells. However, in advanced stages, CTCL may manifest as aggressive clinical behavior and lead to a poor prognosis. The mechanism of disease progression in CTCL remains unknown. Here, with a large clinical cohort, we identified that IKZF2, an essential transcription factor during T cell development and differentiation, showed stage-dependent overexpression in the malignant T cells in MF lesions. IKZF2 is specifically over-expressed in advanced-stage MF lesions, correlates with poor patient prognosis. Mechanistically, IKZF2 overexpression promotes CTCL progression via inhibiting malignant cell apoptosis and may contribute to tumor immune escape by downregulating MHC-II molecules and up-regulating the production of anti-inflammatory cytokine IL-10 by malignant T cells. These results demonstrate the important role of IKZF2 in high-risk CTCL and pave the way for future targeted therapy.

The Th9 Axis Reduces the Oxidative Stress and Promotes the Survival of Malignant T Cells in Cutaneous T-Cell Lymphoma Patients

2020 ◽  
Vol 18 (4) ◽  
pp. 657-668 ◽  
Author(s):  
Sushant Kumar ◽  
Bhavuk Dhamija ◽  
Soumitra Marathe ◽  
Sarbari Ghosh ◽  
Alka Dwivedi ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
T Cells ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Malignant T Cells

IL-32 supports the survival of malignant T cells in cutaneous T cell lymphoma

immuneACCESS ◽  
2021 ◽  
Author(s):  
KK Yu ◽  
NP Smith ◽  
SV Essien ◽  
JE Teague ◽  
P Vieyra-Garcia ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Malignant T Cells

In cutaneous T-cell lymphoma, class II MHC molecules on CD1+ antigen-presenting cells are upregulated in involved compared with uninvolved epidermis

1994 ◽  
Vol 131 (6) ◽  
pp. 780-788 ◽  
Author(s):  
E.R. HANSEN ◽  
B. BANG ◽  
J.K. LARSEN ◽  
G.L. VEJLSGAARD ◽  
O. BAADSGAARD
Keyword(s):  
T Cell ◽  
Cell Lymphoma ◽  
Antigen Presenting Cells ◽  
Class Ii ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Mhc Molecules ◽  
Class Ii Mhc ◽  
Antigen Presenting

scholarly journals Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma

Blood ◽  
2012 ◽  
Vol 119 (15) ◽  
pp. 3534-3538 ◽  
Author(s):  
Filiberto Cedeno-Laurent ◽  
Rei Watanabe ◽  
Jessica E. Teague ◽  
Thomas S. Kupper ◽  
Rachael A. Clark ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Cytokine Production ◽  
Immune Escape ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Tumor Immune Escape ◽  
T Cell Lymphomas ◽  
Malignant T Cells

Tumor-derived galectin-1 (Gal-1), a β-galactoside–binding S-type lectin, has been shown to encourage T-cell death and promote T cell–mediated tumor immune escape. In this report, we show that patients with leukemic cutaneous T-cell lymphomas, known to have limited complexity of their T-cell repertoires, have a predominant T helper type-2 (Th2) cytokine profile and significantly elevated plasma levels of Gal-1 compared with healthy controls. Circulating clonal malignant T cells were a major source of Gal-1. The conditioned supernatant of cultured malignant T cells induced a β-galactoside–dependent inhibition of normal T-cell proliferation and a Th2 skewing of cytokine production. These data implicate Gal-1 in development of the Th2 phenotype in patients with advanced-stage cutaneous T-cell lymphoma and highlight the Gal-1–Gal-1 ligand axis as a potential therapeutic target for enhancing antitumor immune responses.

scholarly journals Monitoring the Decrease of Circulating Malignant T Cells in Cutaneous T-Cell Lymphoma During Photopheresis and Interferon Therapy

2003 ◽  
Vol 139 (7) ◽  
Author(s):  
Katalin Ferenczi ◽  
Nikhil Yawalkar ◽  
David Jones ◽  
Thomas S. Kupper
Keyword(s):  
T Cells ◽  
T Cell ◽  
Interferon Therapy ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cutaneous T Cell Lymphoma ◽  
Malignant T Cells
Sign in / Sign up

Export Citation Format

Share Document